Dr. Elie A. Traer, MD, PhD

Dr. Traer practices at OHSU Hospital in Portland, Oregon, part of State of Oregon.

Dr. Traer's NPI, 1295933729, was assigned on July 5, 2007. Dr. Traer graduated from University of Texas Southwestern Medical School at Dallas in 2006. Dr. Traer holds Oregon license MD28942.

Dr. Traer's primary practice is OHSU Hospital, at 3181 SW Sam Jackson Park Road, Portland, OR 97239 in Multnomah County. The practice phone is (503) 494-9000.

Dr. Traer's primary practice is OHSU Hospital in Portland, Oregon, part of State of Oregon. Dr. Traer is also affiliated with Sky Lakes Medical Center. The medical group on file is Oregon Health & Science University (OHSU). Dmand AI also links Dr. Traer to 1 more clinical lab, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Traer practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Traer's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Traer is licensed in Oregon.

CMS data shows 474 Medicare services from Dr. Traer across 5 procedure codes in 2024, for 84 Medicare patients. Medicare paid $24,704 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 84 Medicare patients who saw Dr. Traer in 2024. The largest group is 65 to 74, with 37 patients. 65% of them have high cholesterol, and 61% have high blood pressure. 18% are also on Medicaid. Their average risk score is 3.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Traer's median patient age at 72, with 38% women.

In 2024, Dr. Traer wrote 662 Medicare Part D claims for 61 patients. 62% of them were for generic drugs. CMS names the drug for 519 of them, across 21 drugs with 11 or more claims each, at $4,211,639 in total drug cost. In 2023, CMS named 323 claims across 12 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 99 out of 100 for Dr. Traer for performance year 2024, reported through an alternative payment model (APM). Dr. Traer accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Traer as offering telehealth.

Dmand AI links 44 papers to Dr. Traer, published from 2014 to 2025. 2023 was the busiest year, with 6. The most frequent topics are Leukemia, Myeloid, Acute, Protein Kinase Inhibitors and Drug Resistance, Neoplasm. Dr. Traer has published most often in Am J Hematol. Dr. Traer's most frequent co-authors are Brian Jay Druker, MD, Jessica Taft Leonard, MD and Ronan Thomas Swords, MD.

Dmand AI links Dr. Traer to 6 clinical trials, 3 of them phase 1 studies. 2 are still active or recruiting. Conditions studied include Leukemia, Myeloid, Acute, Leukemia, Myeloid and Myelodysplastic Syndromes. OHSU Knight Cancer Institute sponsors the most, 2. Open Payments lists research payments to Dr. Traer that name 1 trial.

CMS Open Payments shows 118 general payments to Dr. Traer from 17 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 72% of the total. Incyte Corporation paid the most, $10,559. It also lists 32 research payments totaling $14,925 from 2016 to 2019, naming 1 clinical trial.

Dr. Traer graduated from University of Texas Southwestern Medical School at Dallas in 2006.